厄达替尼作用及功效

Erdafitinib is a once-daily oral pan-fibroblast growth factor receptor that blocks the activity of fibroblast growth factor receptor and is used to treat patients with locally advanced or metastatic urothelial carcinoma who have genetic mutations or fusions in the FGFR2 or FGFR3 genes.

Efficacy of Erdafitinib: Erdafitinib is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who meet the following conditions:

(1) FGFR3 or FGFR2 gene mutation;

(2) Disease progression during or after at least one previous platinum-based chemotherapy regimen, including within 12 months of treatment with neoadjuvant or adjuvant platinum-based chemotherapy regimens.

The efficacy of erdafitinib in the treatment of advanced bladder cancer:

A clinical trial enrolled 87 patients with locally advanced or metastatic bladder cancer who had disease progression during or after at least one chemotherapy regimen and who carried FGFR3 gene mutations or FGFR gene fusions.

The results of the treatment were: the objective response rate ORR (tumor shrinkage by more than 30%) for all patients was 32.2%, the complete response rate CR (tumor disappeared completely) was 2.3%, the partial response rate PR was 29.9%, and the median sustained response time DOR was 5.4 months.

For different types of genetic mutations, the therapeutic effects are different. For patients with FGFR3 point mutations, the objective response rate ORR after treatment is 40.6%; for patients with FGFR3 fusion mutations, the objective response rate ORR is 11.1%; and for patients with FGFR2 fusion mutations, the ORR is 0%, which means the treatment is ineffective.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: